Celgene Corporation (CELG)

[trendmkr]

Celgene Presents Encouraging Phase 2 tnAcity Clinical Trial Results, Decides Not To Pursue Phase 3 http://marketexclusive.com/celgene-corporation-nasdaqcelg-presents-encouraging-phase-2-tnacity-clinical-trial-results-decides-not-pursue-phase-3/42769/?icd1

[trendmkr]

What’s The Deal Between MetaStat And Celgene Corporation? http://marketexclusive.com/whats-deal-metastat-inc-otcmktsmtst-celgene-corporation-nasdaqcelg/33427/?icd1

[trendmkr]

What’s The Deal Between MetaStat And Celgene?
http://marketexclusive.com/whats-deal-metastat-inc-otcmktsmtst-celgene-corporation-nasdaqcelg/33427/?icd1

[georgejjl]

If we can show Prurisol TM to be as effective or better than Otezla®, Prurisol TM should command tremendous value. I believe that companies with marketed biologics will be interested in adding a new, safe and efficacious oral drug to their marketing arsenal and that others looking to enter the psoriasis space will take notice as well. We are not going to leave this type of opportunity on the table by rushing prematurely into Phase 3.

http://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

Good luck and GOD bless,

George

[Deagle]

Scroll down this link to see :
Is Celgene the Smartest Buyer in Biotech?
http://www.fool.com/investing/2016/10/01/better-buy-glaxosmithkline-plc-vs-johnson-johnson.aspx

[georgejjl]

An attractive alternative to Celgene’s OTEZLA

We believe that the potential safety profile of Prurisol may make this an attractive alternative to Celgene’s OTEZLA, which is on its way to achieving $1 billion in sales within just three years of its launch.”

http://cellceutix.com/cellceutix-corporation-provides-business-update-and-timeline-of-upcoming-milestones/#sthash.ocS8l7pM.dpuf

http://cellceutix.com/wp-content/uploads/2014/06/Cellceutix_Corporate_Slide-Deck_DERMATOLOGY-Non-Confidential-July-2016-1-1.pdf


Good luck and GOD bless,

George

[MinnieM]

CELGENE ANNOUNCES INTERIM TOPLINE DATA FROM TRIAL OF INVESTIGATIONAL ORAL GED-0301 IN PATIENTS WITH ACTIVE CROHN’S DISEASE

Data show endoscopic improvement and clinical response and remission at week 12

Safety and tolerability consistent with previous studies

Results expected to be presented at upcoming medical meetings

https://www.sec.gov/Archives/edgar/data/816284/000157104916018192/t1602186_ex99-1.htm

[BananaApes]

Celgene Corp. Inc. Profiled

Stem Cells Market About Therapeutic Benefits Boosts Value of US$119.5 bn in 2018

September 1st, 2016
http://www.medgadget.com/2016/09/stem-cells-market-about-therapeutic-benefits-boosts-value-of-us119-5-bn-in-2018.html

Global Stem Cells Market to Reach US $119.5 Bn by 2018, Rising Awareness About Therapeutic Benefits Boosts Popularity

Published: August 19th, 2016
http://www.sbwire.com/press-releases/stem-cells-market/release-716200.htm?utm_source=djournal&utm_medium=feed&utm_campaign=distribution

"Some of the key enterprises operating in the global stem cells market, namely,...have been profiled in this study."

U.S. Stem Cell / BioHeart Profiled
Symbol: USRM
Shares Outstanding: 14.45M
Float: 12.17M
Stock Price: $0.02

A diamond in the rough or a 100 pound gold nugget?

[Fibanotch]

right on!

[Jld3294]

I think by the end of 2017 Celgene will be near $140. Should easily be $200 by 2020 with upside to $260

[Fibanotch]

140..next year

[venturecapp]

Celgene Corporation, Novartis AG Take Stakes in Flexus Biosciences

http://marketexclusive.com/celgene-corporation-nasdaqcelg-novartis-ag-nysenvs-take-stakes-in-flexus-biosciences/6284/?icd1

[Theo]

Celgene Reports First Quarter 2016 Operating and Financial Results

Strong Operating Momentum Drives Q1 Results

- 2016 Guidance: Raising Lower-End of Ranges for Net Product Sales and Adjusted Diluted EPS

- 2017 Financial Targets Updated; 2020 Financial Targets On-Track

[venturecapp]

Celgene Corporation CMO Joins MetaStat Board

http://marketexclusive.com/celgene-corporation-nasdaq-celg-cmo-joins-metastat-inc-otcmktsmtst-board/6078/

[jondoeuk]

Does anyone know when some updates on CC-90002 will be given?. Thanks

[$Pistol Pete$]

$CELG Daily Chart

[otterman]

Recommended on BNN this morning with a target of $129.

[$Pistol Pete$]

$CELG Daily and Weekly Chart

[$Pistol Pete$]

$CELG Daily Chart

[jimmybob]

Celgene weakness unjustified, says Wells Fargo
After Celgene preannounced lower than expected Q4 EPS and in-line revenue and the stock fell 5%, Wells Fargo says it was encouraged by the company's Q4 revenue and in-line REVLIMID sales. The firm thinks the company's guidance for 2016 and beyond was strong, and it believes the stock is "significantly undervalued

[JLHammer]

http://zolmax.com/investing/celgene-co-celg-rating-increased-to-strong-buy-at-vetr-inc/300537/

[JLHammer]

Hopefullt this will take it higher on Mon. http://ir.celgene.com/releasedetail.cfm?ReleaseID=948466

[JLHammer]

Hard to predict but with that sector having been pounded so much, and the Patent issue out of the way, it's not looking to bad. Only the first day so grabbed some on the dip here for the bounce back up. I'll keep an eye on it. Thank you $CELG

[shez]

Heres what im reading about celgene
www.hungrystreet.com
Im not too optimistic here.

[JLHammer]

$CELG http://www.thestreet.com/story/13409816/1/celgene-celg-stock-buy-rating-reiterated-at-cantor-fitzgerald.html

[jimmybob]

Celgene patent settlement a positive, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer views Celgene's settlement with Natco for the Revlimid Paragraph IV patent challenge as "creative and a positive." The news removes the overhang that allows the company to continue managing towards 25% annual earnings growth through the middle of the next decade, Schimmer tells investors in a research note. The agreement allows a limited generic launch in 2022, the analyst points out. Celgene remains one of his top biotech picks with an Overweight rating and $163 price target

[KICK1]

Anyone selling? CELG

[magness]

Nice pullback from predictable 110 level, still not feeling it either direction... under 109 for a point or so possible fade. No trade

[rmjackson]

Next years valuation
Looking at the numbers for next year, we sit at $5.95. That would put us at $148.75 for next year. I think this VRX ordeal could cause a retest of the lows again for biotech. I know I am waiting for that opportunity should we get it. I am a buyer at and below $110. I still see 28 to 30B in long term peak sales for this current pipeline. Right now we have Revlimid, Abraxane, Pomalyst and Otezla to drive earnings out to 2018 and 2019 when we would see Morgesen and Ozanimod reach the market.

[faxedreceipts]

Lots of shorting today in CELG. Beware of vipers.

[discodave1]

who sold at 1.65?? its that a typo? i see trades that went thru mid 1.60s

[Kyle Miller]

.. Celgene $CELG elects to license a GlobeImmune thyroid-cancer therapy @ByTierraSmith http://t.co/pMJ1SZ6yhO via @denverpost $GILD.

[jimmybob]

Celgene price target raised to $190 from $156 at Canaccord
Canaccord raised its price target on Celgene to $190 from $156 citing its raised guidance for revenues, earnings and margins along with its aggressive M&A strategy and broad pipeline. Canaccord reiterated its Buy rating on Celgene shares

[zetti]

New ath, this moment! Sure this isn't the high for today!!!

[TREND1]

CRLG 30 D W

[TREND1]

Did Receptos Just Give Celgene a Sweetheart Deal?


http://www.fool.com/investing/general/2015/07/15/did-receptos-just-give-celgene-a-sweetheart-deal.aspx?source=eptadnlnk0000002

[TREND1]

EPS = 2.49

[TREND1]

Inst % Owned = 84%

[Joe89]

Smokin move, still holding +8%

[Schekin]

Oh boy! CELG be rockin'! Hugin is one smart cookie!

[Jld3294]

CELG is always a BUY

[jimmybob]

Celgene to acquire Receptos for $232 per share in cash, or about $7.2B
Celgene (CELG) and Receptos (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The acquisition of Receptos significantly enhances Celgene’s Inflammation & Immunology portfolio, further diversifies the company’s revenue beginning in 2019 and beyond, and builds upon Celgene’s growing expertise in inflammatory bowel disease. The transaction adds Ozanimod, a novel, potential best-in-class, oral, once-daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator to Celgene’s deep and diverse pipeline of potential disease-altering medicines and investigational compounds. Celgene will acquire all of the outstanding shares of common stock of Receptos through a tender offer, followed by a second-step merger. In the tender offer, Celgene, through a wholly-owned subsidiary, will offer to purchase all of the outstanding shares of common stock of Receptos for $232.00 per share in cash, or an aggregate of approximately $7.2B, net of cash acquired. The transaction has been approved by the boards of directors of both companies and is subject to customary closing conditions, including the tender of at least a majority of outstanding shares of Receptos common stock and expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is anticipated to close in 2015. Celgene will acquire all remaining shares of Receptos common stock that are not tendered in the tender offer through a second-step merger, which will be completed shortly following the tender offer. Celgene expects to fund the transaction through a combination of existing cash and new debt. The resulting capital structure is consistent with Celgene’s financial strategy and investment grade profile. This acquisition maintains flexibility for additional value creating transactions and share buyback

[Jld3294]

Just entered a starter position at $113

[Jld3294]

Everything I read is showing CELG and GILD as a buy. I'm hoping for market weakness this week to get some CELG at $110 and GILD at $103

[Jld3294]

I just follow the earnings and growth. I get that they are already up big.. But it's not a bubble unless there's no earnings

CELG is proj $6.18 next year compared to the $4.70 this year. That's about 30% growth yoy.

I feel like they aren't really that expensive when factoring growth. CELG has a PEG under 1 which should indicate value.

And GILD has little growth but will probably be making a big splash soon IMO.

[jimmybob]

most of these bios now are up insane amounts... If, on this day 5 years ago you bought $REGN +1,790% | $BIIB +713% | $CELG +316% | $GILD +498% | $IBB +354%

So hard for me to even thing some of these bios are good investments in the next 5-10 years... but figure most were saying that with REGN at $200... $300... now its $500 and likely 700-800 soon ~

[Jld3294]

For a young investor looking to buy. biotech should I go with CELG for the growth or GILD for the value buy?

Or just go IBB any opinions??

[jimmybob]

Celgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares

[bundyelvis]

Ouch. I did sell yesterday at 113.17. I had second thoughts and played it safe.

[Black sunshine]

Isn't that just a rumor?